Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial.
The Lancet ( IF 98.4 ) Pub Date : 2017-09-01 , DOI: 10.1016/s2213-2600(17)30234-5
Valerie J Page ₁ , Annalisa Casarin ₂ , E Wesley Ely ₃ , Xiao Bei Zhao ₄ , Cliona McDowell ₅ , Lynn Murphy ₅ , Daniel F McAuley ₆

Affiliation

Delirium in critically ill patients is associated with poor clinical outcomes. Neuroinflammation might be an important mechanism in the pathogenesis of delirium, and since simvastatin has anti-inflammatory properties it might reduce delirium. We aimed to establish whether early treatment with simvastatin would decrease the time that survivors of critical illness spent in delirium or coma.

中文翻译：

评估早期给予辛伐他汀预防和治疗接受机械通气 (MoDUS) 的危重患者谵妄：一项随机、双盲、安慰剂对照试验。

重症患者的谵妄与不良的临床结果相关。神经炎症可能是谵妄发病机制中的一个重要机制，并且由于辛伐他汀具有抗炎特性，它可能会减少谵妄。我们旨在确定辛伐他汀的早期治疗是否会减少危重病幸存者谵妄或昏迷的时间。

更新日期：2017-08-10

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文